<DOC>
	<DOCNO>NCT00471367</DOCNO>
	<brief_summary>This study two part ( A B ) . The primary purpose Part A find maximum tolerate dose experimental drug call AZD4877 base side effect experience patient receive AZD4877 twice week basis . For Part B , additional 20 patient treated maximum dose identify Part A. AZD4877 Eg5 Kinesin Spindle Protein inhibitor interfere tumor cell division lead tumor growth</brief_summary>
	<brief_title>Phase I , Open-label , Dose-escalation , Safety PK Study AZD4877</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Part A : Advanced solid tumor ( include lymphoma without bone marrow involvement ) standard treatment n't exist longer effective . Part B : Bcell nonHodgkin lymphoma eligible curative therapy relapse . Relatively good overall health cancer Poor bone marrow function ( produce enough blood cell ) . Serious heart condition . Poor liver kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AZD4877</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>B-cell non-Hodgkin lymphoma</keyword>
</DOC>